Os tumores do sistema nervoso central representam aproximadamente 2% de todos os tipos de cânceres. Embora a incidência dos tumores do SNC seja pequena, comparada com outras neoplasias, estes tumores estão entre as mais graves malignidades humanas, pois afetam o órgão responsável pela coordenação e integração de todas as atividades orgânicas. Os gliomas são os tumores mais comuns do SNC. Apesar do progresso marcante na caracterização da patogênese molecular dos gliomas, esses tumores permanecem incuráveis e, na maioria dos casos, refratários aos tratamentos, devido à sua heterogeneidade molecular. O aparecimento desses tumores ocorrem a partir do acúmulo de alterações genéticas nas células. Para entender o mecanismo molecular de formação e progressão tumoral é indispensável identificar os genes que acumulam essas alterações. Um polimorfismo de base única (SNP Single Nucleotide Polymorphism) é geralmente definido como uma substituição estável de apenas uma base na molécula de DNA com frequência maior que 1%, em pelo menos uma população Os SNPs são reconhecidos como importantes ferramentas na genética humana e médica e têm sido amplamente utilizados nos estudos de associação genética de várias doenças complexas, como por exemplo: distúrbios cardiovasculares, psiquiátricos e autoimunes, obesidade, osteoporose, diabetes e câncer Sendo assim, este trabalho teve como objetivo analisar polimorfismos entre populações caso e controle na intenção de identificar associações destes genótipos na suscetibilidade aos tumores. A técnica utilizada para a análise de polimorfismos foi de PCR-RFLP onde observamos diferenças nas distribuições genotípicas entre pacientes e controles nos SNPs EGF+61, GSTP-1Ile 105 Val, XRCC1 Arg 194 Trp, Pro 206 Pro, Arg 280 His, Arg 399 Gln, Gln 632 Gln, XRCC2 Arg 188 His, XRCC3 Thr 241 Met e XRCC4 G1394T, onde as variantes EGF G61, Trp194, Val105, Pro206, His280, Gln632, His188, Met241 e XRCC4 T1394 foram observados com maior freqüência entre os portadores de gliomas. Dessa forma, estas variantes podem ser fatores de susceptibilidade para o desenvolvimento dos tumores. / The Central nervous system tumors represent about 2% of all cancers. Although the incidence of CNS tumors is small compared with other cancers, these tumors are among the most serious human malignancies, because they affect the body responsible for coordination and integration of all organic activities. Gliomas are the most common tumors of the CNS. Despite remarkable progress in characterizing the molecular pathogenesis of gliomas, these tumors remain incurable and, in most cases, refractory to treatment, due to its molecular heterogeneity. The appearance of these tumors occurs from the accumulation of genetic changes in cells. To understand the molecular mechanism of tumor formation and progression is essential to identify genes that accumulate these changes. A single base polymorphism (SNP Single Nucleotide Polymorphism) is generally defined as a stable replacement of only one base in the DNA molecule often greater than 1% in at least one population SNPs are recognized as important tools in human genetics and medical and have been widely used in genetic association studies of various complex diseases, such as: cardiovascular, psychiatric and autoimmune diseases, obesity, osteoporosis, diabetes and cancer. Thereby, the objective of this study was to analyze the polymorphisms between cases and control the intention to identify associations of these genotypes in susceptibility to tumors. The technique used for the analysis of polymorphisms were PCR-RFLP where we observe differences in genotype between patients and controls in the EGF +61, GSTP-1 Ile105Val, XRCC1 Arg 194 Trp, Pro 206 Pro, Arg 280 His, Arg 399 Gln, Gln 632 Gln, XRCC2 Arg 188 His, XRCC3 Thr 241 Met and XRCC4 G1394T, where the variants EGF G61, Trp194, val105, Pro206, His280, Gln632, His188, Met241 and XRCC4 T1394 were observed more frequently among patients with gliomas. Thus, these variants can be important factors of susceptibility to the tumor development.

Os tumores do sistema nervoso central representam aproximadamente 2% de todos os tipos de cânceres. Embora a incidência dos tumores do SNC seja pequena, comparada com outras neoplasias, estes tumores estão entre as mais graves malignidades humanas, pois afetam o órgão responsável pela coordenação e integração de todas as atividades orgânicas. Os gliomas são os tumores mais comuns do SNC. Apesar do progresso marcante na caracterização da patogênese molecular dos gliomas, esses tumores permanecem incuráveis e, na maioria dos casos, refratários aos tratamentos, devido à sua heterogeneidade molecular. O aparecimento desses tumores ocorrem a partir do acúmulo de alterações genéticas nas células. Para entender o mecanismo molecular de formação e progressão tumoral é indispensável identificar os genes que acumulam essas alterações. Um polimorfismo de base única (SNP Single Nucleotide Polymorphism) é geralmente definido como uma substituição estável de apenas uma base na molécula de DNA com frequência maior que 1%, em pelo menos uma população Os SNPs são reconhecidos como importantes ferramentas na genética humana e médica e têm sido amplamente utilizados nos estudos de associação genética de várias doenças complexas, como por exemplo: distúrbios cardiovasculares, psiquiátricos e autoimunes, obesidade, osteoporose, diabetes e câncer Sendo assim, este trabalho teve como objetivo analisar polimorfismos entre populações caso e controle na intenção de identificar associações destes genótipos na suscetibilidade aos tumores. A técnica utilizada para a análise de polimorfismos foi de PCR-RFLP onde observamos diferenças nas distribuições genotípicas entre pacientes e controles nos SNPs EGF+61, GSTP-1Ile 105 Val, XRCC1 Arg 194 Trp, Pro 206 Pro, Arg 280 His, Arg 399 Gln, Gln 632 Gln, XRCC2 Arg 188 His, XRCC3 Thr 241 Met e XRCC4 G1394T, onde as variantes EGF G61, Trp194, Val105, Pro206, His280, Gln632, His188, Met241 e XRCC4 T1394 foram observados com maior freqüência entre os portadores de gliomas. Dessa forma, estas variantes podem ser fatores de susceptibilidade para o desenvolvimento dos tumores. / The Central nervous system tumors represent about 2% of all cancers. Although the incidence of CNS tumors is small compared with other cancers, these tumors are among the most serious human malignancies, because they affect the body responsible for coordination and integration of all organic activities. Gliomas are the most common tumors of the CNS. Despite remarkable progress in characterizing the molecular pathogenesis of gliomas, these tumors remain incurable and, in most cases, refractory to treatment, due to its molecular heterogeneity. The appearance of these tumors occurs from the accumulation of genetic changes in cells. To understand the molecular mechanism of tumor formation and progression is essential to identify genes that accumulate these changes. A single base polymorphism (SNP Single Nucleotide Polymorphism) is generally defined as a stable replacement of only one base in the DNA molecule often greater than 1% in at least one population SNPs are recognized as important tools in human genetics and medical and have been widely used in genetic association studies of various complex diseases, such as: cardiovascular, psychiatric and autoimmune diseases, obesity, osteoporosis, diabetes and cancer. Thereby, the objective of this study was to analyze the polymorphisms between cases and control the intention to identify associations of these genotypes in susceptibility to tumors. The technique used for the analysis of polymorphisms were PCR-RFLP where we observe differences in genotype between patients and controls in the EGF +61, GSTP-1 Ile105Val, XRCC1 Arg 194 Trp, Pro 206 Pro, Arg 280 His, Arg 399 Gln, Gln 632 Gln, XRCC2 Arg 188 His, XRCC3 Thr 241 Met and XRCC4 G1394T, where the variants EGF G61, Trp194, val105, Pro206, His280, Gln632, His188, Met241 and XRCC4 T1394 were observed more frequently among patients with gliomas. Thus, these variants can be important factors of susceptibility to the tumor development.

No description available.

Após o seqüenciamento completo do genoma humano, a busca e caracterização do conjunto completo de genes humanos constitui-se no principal desafio nesta área de investigação, sendo o passo limitante para o progresso na exploração dos dados contidos no seqüenciamento deste genoma. O projeto de transcriptoma denominado \"Transcript Finishing Initiative\" (TFI) surgiu neste contexto, com o objetivo principal de gerar fragmentos parciais de transcritos humanos, que não haviam sido descritos previamente e determinar sua seqüência, para iniciar a caracterização de novos genes humanos. A estratégia utilizada foi q alinhamento de todas as seqüências ORESTES e ESTs disponíveis com a seqüência pública do genoma humano e o agrupamento j c1usterização destas com base nas coordenadas deste genoma. Algumas das regiões que não eram cobertas por estas seqüências foram, então, completadas, por RT-PCR, utilizando-se primers ancorados nos clusters vizinhos. Cada par de clusters de ESTs selecionado para validação experimental foi designado como uma Unidade do \"Transcript Finishing\" (TFU), tendo sido validadas experimentalmente, pelo grupo TFI, Um total de 211 TFUs foram validadas, sendo que 197 seqüências consenso foram submetidas ao Genbank (CF272536-CF272733). Atualmente, apenas um pequeno número destas seqüências ainda são considerados genes novos, sem que haja um cDNA depositado em banco de dados; contudo para um número considerável destas TFUs não existe qualquer caracterização sobre sua função. Na tentativa de contribuir para melhor caracterização dos genes identificados no projeto TFI, e tendo, como base, a linha de pesquisa do laboratório, que busca genes diferencialmente expressos envolvidos em transformação maligna/tumorigênese, o presente trabalho propôs a utilização das seqüências TFUs para estudar sua possível associação com tumores de glia humanos e outros tipos de tumores (de próstata e de mama). Para tanto, as TFUs foram analisadas \"in silico\" para estabelecer seu grau de ineditismo como um novo gene ou um gene sem função conhecida, e, para análise de sua expressão diferencial entre tecidos normais e tumorais de cérebro, próstata e mama. Para validar estas análises computacionais na bancada, foram gerados macro- e microarranjos de DNA utilizando-se as TFUs disponíveis como clones físicos ou amplicons, para o rastreamento com sondas das linhagens celulares A172 e T98G de glioblastomas. Os resultados das análises destes dados foram confirmados por PCR quantitativo tanto nas linhagens como em amostras clínicas de astrocitomas que apresentam diversos graus de malignidade. Como resultado, foi possível organizar um Banco de Clones Físicos de TFUs, além de identificar e selecionar uma TFU (168), cuja expressão correlaciona diretamente com o grau de malignidade dos tumores de glia. Esta seqüência corresponde a um novo gene, já que não existe a seqüência de cDNA completo nos bancos de dados. Em vista disto, a TFU168 foi selecionada para estudos funcionais posteriores, que já estão em andamento, através da obtenção de suaseqüência completa de cDNA para ensaios de superexpressão e do silenciamento gênico através de RNAi. / Upon complete sequencing of the human genome, identification and characterization of the complete set of human genes constitutes the major challenge in this research field, constituting the limiting step for progress in exploration of the informations contained in the genome sequencing data. The Transcript Finishing Initiative (TFI) transcriptome project arose in this context, aiming at the generation, sequencing and characterization of partial new human transcripts and genes. The strategy adopted was the alignment of the alI the available ORESTES and EST sequences data with the public human genome sequence and their clusterization based on the coordinates of this genome. Thus, some of the regions which were not cover by ESTs and ORESTES (gaps) were then completed by RT-PCR using primers anchored in the neighboring clusters. Each pair of EST clusters selected for experimental validation was named Transcript Finishing Unit (TFU). A large number (211) of TFU s were validated and 197 -consensus sequences were submitted to the Genbank (CF272536-CF272733). At present, only a few of these sequences are considered as new genes without a full-Iength cDNA sequence deposited in the data bank, however, no functional characterization is yet available for a large number of these sequences. In an attempt to contribute to further characterization of these genes identified in the TFI project and keeping in mind the main interest of our laboratory, which is the identification of differentially expressed genes in tumor versus normal tissue, the present work aims at utilizing these TFUs to find differentially expressed genes associated with human glial tumors and with other kinds of tumors. To this end, these sequences were first subjected to in silico analysis in order to establish their degree of ineditism (new sequences and/or sequences with unknown function) and their expression profile between normal and tumoral tissues of brain, mammary gland and prostate. To validate this computational analysis, DNA macro- and microarrays were generated with the TFU sequences and screened with cDNA probes obtained from the A172 and T98G glioblastomas cell lines. The results of these screenings were confirmed by quantitative PCR both in cell lines and in tumor samples of different degrees of malignancy. The results obtained in this work allowed the organization of a TFUs Physical Clones Bank and the identification and selection of one sequence (TFU 168), whose expression is directly re1ated to the degree of tumor malignancy. This sequence constitutes a new gene, since no complete cDNA sequence is available in the data banks. Therefore, TFU168 was selected for further functional studies by obtaining its full-Iength cDNA sequence to be used for over expression by silencing this gene using RNAi.

Após o seqüenciamento completo do genoma humano, a busca e caracterização do conjunto completo de genes humanos constitui-se no principal desafio nesta área de investigação, sendo o passo limitante para o progresso na exploração dos dados contidos no seqüenciamento deste genoma. O projeto de transcriptoma denominado \"Transcript Finishing Initiative\" (TFI) surgiu neste contexto, com o objetivo principal de gerar fragmentos parciais de transcritos humanos, que não haviam sido descritos previamente e determinar sua seqüência, para iniciar a caracterização de novos genes humanos. A estratégia utilizada foi q alinhamento de todas as seqüências ORESTES e ESTs disponíveis com a seqüência pública do genoma humano e o agrupamento j c1usterização destas com base nas coordenadas deste genoma. Algumas das regiões que não eram cobertas por estas seqüências foram, então, completadas, por RT-PCR, utilizando-se primers ancorados nos clusters vizinhos. Cada par de clusters de ESTs selecionado para validação experimental foi designado como uma Unidade do \"Transcript Finishing\" (TFU), tendo sido validadas experimentalmente, pelo grupo TFI, Um total de 211 TFUs foram validadas, sendo que 197 seqüências consenso foram submetidas ao Genbank (CF272536-CF272733). Atualmente, apenas um pequeno número destas seqüências ainda são considerados genes novos, sem que haja um cDNA depositado em banco de dados; contudo para um número considerável destas TFUs não existe qualquer caracterização sobre sua função. Na tentativa de contribuir para melhor caracterização dos genes identificados no projeto TFI, e tendo, como base, a linha de pesquisa do laboratório, que busca genes diferencialmente expressos envolvidos em transformação maligna/tumorigênese, o presente trabalho propôs a utilização das seqüências TFUs para estudar sua possível associação com tumores de glia humanos e outros tipos de tumores (de próstata e de mama). Para tanto, as TFUs foram analisadas \"in silico\" para estabelecer seu grau de ineditismo como um novo gene ou um gene sem função conhecida, e, para análise de sua expressão diferencial entre tecidos normais e tumorais de cérebro, próstata e mama. Para validar estas análises computacionais na bancada, foram gerados macro- e microarranjos de DNA utilizando-se as TFUs disponíveis como clones físicos ou amplicons, para o rastreamento com sondas das linhagens celulares A172 e T98G de glioblastomas. Os resultados das análises destes dados foram confirmados por PCR quantitativo tanto nas linhagens como em amostras clínicas de astrocitomas que apresentam diversos graus de malignidade. Como resultado, foi possível organizar um Banco de Clones Físicos de TFUs, além de identificar e selecionar uma TFU (168), cuja expressão correlaciona diretamente com o grau de malignidade dos tumores de glia. Esta seqüência corresponde a um novo gene, já que não existe a seqüência de cDNA completo nos bancos de dados. Em vista disto, a TFU168 foi selecionada para estudos funcionais posteriores, que já estão em andamento, através da obtenção de suaseqüência completa de cDNA para ensaios de superexpressão e do silenciamento gênico através de RNAi. / Upon complete sequencing of the human genome, identification and characterization of the complete set of human genes constitutes the major challenge in this research field, constituting the limiting step for progress in exploration of the informations contained in the genome sequencing data. The Transcript Finishing Initiative (TFI) transcriptome project arose in this context, aiming at the generation, sequencing and characterization of partial new human transcripts and genes. The strategy adopted was the alignment of the alI the available ORESTES and EST sequences data with the public human genome sequence and their clusterization based on the coordinates of this genome. Thus, some of the regions which were not cover by ESTs and ORESTES (gaps) were then completed by RT-PCR using primers anchored in the neighboring clusters. Each pair of EST clusters selected for experimental validation was named Transcript Finishing Unit (TFU). A large number (211) of TFU s were validated and 197 -consensus sequences were submitted to the Genbank (CF272536-CF272733). At present, only a few of these sequences are considered as new genes without a full-Iength cDNA sequence deposited in the data bank, however, no functional characterization is yet available for a large number of these sequences. In an attempt to contribute to further characterization of these genes identified in the TFI project and keeping in mind the main interest of our laboratory, which is the identification of differentially expressed genes in tumor versus normal tissue, the present work aims at utilizing these TFUs to find differentially expressed genes associated with human glial tumors and with other kinds of tumors. To this end, these sequences were first subjected to in silico analysis in order to establish their degree of ineditism (new sequences and/or sequences with unknown function) and their expression profile between normal and tumoral tissues of brain, mammary gland and prostate. To validate this computational analysis, DNA macro- and microarrays were generated with the TFU sequences and screened with cDNA probes obtained from the A172 and T98G glioblastomas cell lines. The results of these screenings were confirmed by quantitative PCR both in cell lines and in tumor samples of different degrees of malignancy. The results obtained in this work allowed the organization of a TFUs Physical Clones Bank and the identification and selection of one sequence (TFU 168), whose expression is directly re1ated to the degree of tumor malignancy. This sequence constitutes a new gene, since no complete cDNA sequence is available in the data banks. Therefore, TFU168 was selected for further functional studies by obtaining its full-Iength cDNA sequence to be used for over expression by silencing this gene using RNAi.

Glioblastoma multiforme is the most aggressive form of malignant brain tumor with poor prognosis. The efficacy of brain cancer treatment by chemotherapeutics is limited by the blood-brain barrier (BBB) which allows less than 2% of the small molecules and blocks almost all the macromolecules to transport into the brain. Delivery of the large molecules such as proteins and nucleic acids across the BBB is a great challenge for brain-targeted drug delivery. To overcome this obstacle, cell-penetrating peptides (CPPs) were used as vectors for delivery of nucleic acids across the BBB targeting glioblastomas. The CPPs have shown such promising carriers to deliver various cargoes ranging from small molecules to large molecules into the cells. This thesis is focused on the development of glioblastoma-targeting vectors based on modifications of the CPPs and the targeting peptides. The peptide-based vectors were developed to improve the transport of the nucleic acids across the BBB and specifically target glioblastomas. In this thesis, a series of peptide-based vectors targeting glioblastomas were synthesized and modified with targeting peptides by either covalent conjugation or non-covalent complex formation. The delivery of plasmid DNA (pDNA) in the complex with the peptide-based vectors was studied in the in vitro model of the BBB. The role of receptors expressed on the BBB was investigated. Scavenger receptors class A and B were found to be expressed on the BBB, and they were involved in the delivery of the pDNA across the BBB model. Moreover, various targeting peptides were modified with hexaglutamate to form non-covalent complexes with the CPPs for small interfering RNA (siRNA) delivery to glioblastoma cells. The non-covalent complex of the CPP and the targeting peptide showed greater gene-silencing efficiency than the consecutively covalent conjugation of the CPP and the targeting peptide for siRNA delivery to glioblastoma cells. Lastly, a number of novel, amphipathic peptides were developed based on the model amphipathic peptide. The prediction of the biological effect of the designed peptides using quantitative structure-activity relationship model showed a correlation with the experimental data. Finally, the CPP-based nucleic acid delivery vectors with homing peptide strategy have a potential for the BBB shuttle and the future use as a glioblastoma-targeted drug carrier in the in vivo studies and the clinical applications. / <p>At the time of the doctoral defense, the following paper was unpublished and had a status as follows: Paper 4: Manuscript.</p>

202f. / Submitted by Ana Hilda Fonseca (anahilda@ufba.br) on 2013-04-01T14:56:04Z No. of bitstreams: 2 Folhas pre-textuais.pdf: 503924 bytes, checksum: b9d325ed66778f4e910714d66cd05f1a (MD5) corpo da tese final.pdf: 8015036 bytes, checksum: 267d671ad10dffcd21ca5da18e1daa67 (MD5) / Rejected by Ana Hilda Fonseca(anahilda@ufba.br), reason: Pedir ao aluno para colocar em um só arquivo. on 2013-04-24T15:29:06Z (GMT) / Submitted by Ana Hilda Fonseca (anahilda@ufba.br) on 2013-05-20T17:38:16Z No. of bitstreams: 1 Tese Edson de Jesus Marques.pdf: 8119670 bytes, checksum: 0f527c5cdd0e076e00e338d2fc003d4c (MD5) / Approved for entry into archive by Ana Hilda Fonseca(anahilda@ufba.br) on 2013-05-20T17:40:15Z (GMT) No. of bitstreams: 1 Tese Edson de Jesus Marques.pdf: 8119670 bytes, checksum: 0f527c5cdd0e076e00e338d2fc003d4c (MD5) / Made available in DSpace on 2013-05-20T17:40:15Z (GMT). No. of bitstreams: 1 Tese Edson de Jesus Marques.pdf: 8119670 bytes, checksum: 0f527c5cdd0e076e00e338d2fc003d4c (MD5) Previous issue date: 2011 / CAPES / Este trabalho teve como objetivos realizar o isolamento, identificar compostos extraídos do caule de Clusia criuva e determinar a atividade citotóxica, in vitro, para células GL-15 de glioblastoma humano. Foram utilizados extratos obtidos com hexano e com diclorometano. O fracionamento foi feito por técnicas cromatográficas de gel de sílica e em camada delgada. A identificação das moléculas foi realizada com base na análise dos dados obtidos por diferentes técnicas espectroscópicas, propriedades físicas e comparação com dados da literatura. Foram identificados vinte e cinco metabolitos, sendo sete benzofenonas, a sampsoniona B (S03), as propolonas A (S06), B (S07), C (S04) e D (S05), o criuvanol I (S01) e II (S02); quatro xantonas, a brasilixantona B (S09), a osajaxantona F (S21), a 6-deoxijacareubina (S16) e a 1,5dihidroxi-3-4-[2”-hidroxi-1-metiletil-dihidrofurano]-xantona (S08); duas bifenilas, a aucuparina (S10) e a 2,2-dimetil-5-hidroxi-7-fenilcromeno (S15); cinco triterpenos, a friedelina (S18), o friedelinol (S19), o lupeol (S25), o ácido betulínico (S12) e o ácido betulínico esterificado pelo feruloil em C-28 (S11); cinco esteróides, o ϐ-sitosterol (S23), a sitostenona (S22), o lanosterol (S20), o estigmasterol (S17) e o sitosterol esterificado por ácido graxo saturado em C-3 (S24); dois tocotrienóis, os ácidos δ-tocotrienóis cis e trans (S13 e S14). A xantona S08 e as benzofenonas, criuvanol I e criuvanol II, são compostos inéditos. Para avaliação da atividade citotóxica foi utilizado como modelo experimental células GL-15 de glioblastomas humano. As células foram cultivadas em placas de 96 poços e mantidas em estufa a 37 ºC, com 5% de CO2 por 72 h. Foram avaliadas as substâncias S01 a S05, S07, S08, S10 a S14 e S22. Nessas condições, todas apresentaram potencial citotóxico superior a temozolomida, sendo os mais potentes o ácido betulínico, o criuvanol I e a propolona D. A atividade citotóxica (EC50) apresentada por cada uma delas foi de 29,2, 18,3 e 19,3 μM, respectivamente. / Salvador

Astrocytoma, the tumor of astrocytic origin, accounts for about 60 % of the primary brain tumors. As per World Health Organization grading system, astrocytoma is classified as circumscribed astrocytoma (Grade I; pilocytic astrocytoma) and diffusely infiltrating astrocytoma. Grade I tumor is biologically benign and can be cured by surgical resection of the tumor. The diffusely infiltrating astrocytoma is further subclassified into grade II/diffuse astrocytoma (DA), grade III/anaplastic astrocytoma (AA) and grade IV/glioblastoma (GBM). Aggressiveness of the disease increases as the tumor progresses from lower grade to higher grade. In particular, GBMs are the most malignant and aggressive human cancers. For a newly diagnosed GBM patient, the current treatment option is surgical resection of the tumor followed by radiation and temozolomide therapy. Despite the treatment is multimodal (surgery+radiation+temozolomide) the median survival of GBM patients remain very low at 14.6 months. Although numerous markers with potential utility in prognosis and treatment of GBMs have been reported, they are yet to be translated into clinical utility. Our knowledge of understanding the complete biology of GBMs needs further comprehensive studies towards the identification of markers with potential utility to prognose/treat the GBM patients efficiently. Therefore, with an immense need to develop new biomarkers/therapeutic strategies in order to improve the diagnosis, prognosis and existing treatment of the GBM, the current work is designed to study the following aspects on glioma

Η πλειοτροπίνη (PTN) αποτελεί έναν αυξητικό παράγοντα με ποικίλες δράσεις και σημαντικό ρόλο στην ανάπτυξη όγκων και την αγγειογένεση. Διάφοροι υποδοχείς αλληλεπιδρούν με την ΡΤΝ και διαμεσολαβούν τις βιολογικές της δράσεις, όπως η Ν-συνδεκάνη, ο ALK (κινάση αναπλαστικού λεμφώματος) και ο RPTPβ/ζ (υποδοχέας με δράση φωσφατάσης τυροσίνης β/ζ). Η ερευνητική μας ομάδα έχει δείξει σε προηγούμενη μελέτη ότι η ικανότητα της PTN να επάγει κυτταρική μετανάστευση εξαρτάται από το σχηματισμό ενός λειτουργικού συμπλόκου που αποτελείται από τον RPTPβ/ζ και την ιντεγκρίνη ανβ3. Η πολυ-λειτουργική πρωτεΐνη νουκλεολίνη (NCL), η οποία υπερεκφράζεται στην επιφάνεια ενεργοποιημένων ενδοθηλιακών και καρκινικών κυττάρων και διαμεσολαβεί τις διεγερτικές δράσεις διαφόρων αγγειογενετικών παραγόντων, έχει επίσης προταθεί ως υποδοχέας χαμηλής συγγένειας για την ΡΤΝ, με άγνωστες όμως λειτουργίες. Στην παρούσα μελέτη δείξαμε, με τη χρήση μεθόδων ανοσοκατακρήμνισης-ανοσοαποτυπώματος, διπλού ανοσοφθορισμού και προσδιορισμού αλληλεπίδρασης λόγω εγγύτητας, ότι η PTN αλληλεπιδρά άμεσα με τη NCL. Η αλληλεπίδραση αυτή περιλαμβάνει πρόσδεση της αμινοτελικής περιοχής της ΡΤΝ (αμινοξέα: 16-24) στην κεντρική περιοχή της NCL (αμινοξέα: 308-645). Μείωση της έκφρασης της NCL με siRNA ή λειτουργική αναστολή της μεμβρανικής NCL από το πεπτίδιο 5(KPR)TASP ανέστειλε πλήρως την επαγόμενη από ΡΤΝ μετανάστευση ενδοθηλιακών κυττάρων. Με αφετηρία την παρατήρηση ότι ο εντοπισμός της NCL στην κυτταρική επιφάνεια ανιχνεύθηκε μόνο σε κύτταρα που εκφράζουν την ανβ3, και πραγματοποιώντας πειράματα ανοσοφθορισμού και βιοχημικές μελέτες σε κύτταρα με γενετικά τροποποιημένη έκφραση των υπό μελέτη μορίων, δείξαμε ότι ο εντοπισμός της NCL στην πλασματική μεμβράνη εξαρτάται από τη φωσφορυλίωση της β3 στην τυροσίνη 773 μέσω ενεργοποίησης του RPTPβ/ζ και της c-src. Καθοδικά της ανβ3, η PI3K συμμετέχει σε αυτή τη δράση. Ο VEGF165 που επίσης επάγει το μεμβρανικό εντοπισμό της NCL, δρα μέσω δέσμευσης στον RPTPβ/ζ και ενεργοποίησης του σηματοδοτικού μονοπατιού RPTPβ/ζ/c-src/ανβ3. Η περιοχή δέσμευσης στους υποδοχείς VEGFR-1 και VEGFR-2 ή η περιοχή δέσμευσης στην ηπαρίνη στο μόριο του VEGF165 δεν εμπλέκονται στον επαγόμενο από VEGF165 εντοπισμό της NCL στην κυτταρική μεμβράνη. Εκτός από την PI3K, στη δράση του VEGF165 καθοδικά της ανβ3 εμπλέκεται και η κινάση p38, η ενεργοποίηση της οποίας είναι ανεξάρτητη από τον RPTPβ/ζ και τη φωσφορυλίωση της β3 στις τυροσίνες 773 ή 785, και φαίνεται να ανήκει σε μονοπάτι που ενεργοποιείται παράλληλα και που παραμένει αδιευκρίνιστο. Μηχανιστικά, η NCL βρέθηκε να αλληλεπιδρά άμεσα με την ανβ3, τον RPTPβ/ζ, τον VEGF165 και τον VEGFR-2, αλλά επηρεάζει τον ενδοκυτταρικό εντοπισμό μόνο του RPTPβ/ζ και της PTN. Θετική συσχέτιση παρατηρήθηκε ως προς την έκφραση της μεμβρανικής NCL και της ανβ3 σε μικροσυστοιχίες ιστών προερχόμενων από ανθρώπινα γλοιοβλαστώματα. Τέλος, βρέθηκε ότι το μονοκλωνικό αντίσωμα anti-C23 και τα πεπτίδια που στοχεύουν τη μεμβρανική NCL, 5(KPR)TASP, ΗΒ-19 και Nucant 6L, ανέστειλλαν σημαντικά τη μετανάστευση κυττάρων που εκφράζουν ανβ3, ενώ είχαν μικρή ή καθόλου δράση στη μετανάστευση κυττάρων που δεν εκφράζουν ανβ3 ή υπερεκφράζουν μετάλλαγμα της β3 με αντικατάσταση της κυτταροπλασματικής τυροσίνης 773 σε φαινυλαλανίνη. Συνολικά, από τα αποτελέσματα της παρούσας διατριβής προκύπτει ότι η έκφραση της ανβ3 και η φωσφορυλίωση της β3 στην τυροσίνη 773 καθορίζουν τον εντοπισμό της NCL στην κυτταρική επιφάνεια, καθοδικά του σηματοδοτικού μονοπατιού RPTPβ/ζ/c-src που συμμετέχει στην κυτταρική μετανάστευση που επάγεται τόσο από την ΡΤΝ, όσο και από τον VEGF165. Επίσης, φαίνεται ότι η έκφραση της ανβ3 θα μπορούσε να χρησιμοποιηθεί ως βιοδείκτης για τη χρήση ανταγωνιστών της μεμβρανικής NCL ως αντικαρκινικών παραγόντων. / Pleiotrophin (PTN) is a growth factor that plays a significant role on tumor growth and angiogenesis. Several receptors interact with PTN and mediate its biological actions, such as N-syndecan, anaplastic lymphoma kinase (ALK) and receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ). Our group has previously shown that the ability of PTN to stimulate migratory responses depends on the formation of a functional complex consisting of RPTPβ/ζ and integrin ανβ3. The multifunctional protein nucleolin (NCL), which is over-expressed on the surface of activated endothelial and tumor cells and mediates the stimulatory actions of several angiogenic factors, has been also suggested as a low affinity receptor for PTN, however with unknown functions. In the present study, by using immunoprecipitation/Western blot analyses, double immunofluorescence and proximity ligation assays, we showed that PTN directly interacts with NCL. This interaction involves binding of the amino-terminal domain of PTN (amino acids: 16-24) to the central domain of NCL (amino acids: 308-645). Down-regulation of NCL by siRNA or blockage of cell surface NCL by its ligand 5(KPR)TASP completely abolished PTN-induced endothelial cell migration. Based on the observation that cell surface NCL localization was detected only in cells expressing ανβ3 and by performing immunofluorescence and biochemical studies in cells with genetically altered expression of the studied molecules, we demonstrated that cell surface NCL localization depends on the phosphorylation of β3 at Tyr773 through RPTPβ/ζ and c-src activation. Down-stream of ανβ3, PI3K activity is required for cell surface NCL localization. VEGF165 that also induces cell surface NCL localization acts through binding to RPTPβ/ζ and activation of the RPTPβ/ζ/c-src/ανβ3 signaling pathway. The receptor or the heparin binding sites on the VEGF165 molecule do not seem to be involved in this VEGF165 action. Apart from PI3K, in VEGF165-induced cell surface NCL localization, p38 that lays down-stream of ανβ3, is also involved. Activation of p38 is independent of RPTPβ/ζ and β3 Tyr773 or Tyr785 phosphorylation, and seems to belong to a parallel signaling pathway that remains unclear. Mechanistically, NCL was found to directly interact with ανβ3, RPTPβ/ζ, VEGF165 and VEGFR-2, but only affects the intracellular localization of RPTPβ/ζ and PTN. Positive correlation of cell surface NCL and ανβ3 expression was observed in human glioblastoma tissue arrays. Finally, the monoclonal antibody anti-C23 and the peptides targeting cell surface NCL, 5(KPR)TASP, HB-19 and Nucant 6L, significantly inhibited migration of cells expressing ανβ3 in the presence of serum, while they had a minor or no effect on cells lacking ανβ3 or over-expressing mutant β3 with replacement of cytoplasmic tyrosine 773 to phenylalanine. Collectively, these data suggest that ανβ3 expression and β3 phosphorylation at Tyr773 downstream of the RPTPβ/ζ/c-src signaling cascade determines the cell surface localization of NCL, which is required for cell migration induced by both PTN and VEGF165. Moreover, expression of ανβ3 could be used as a biomarker for the use of cell surface NCL antagonists as anticancer agents.

Les glioblastomes (GBs) sont les tumeurs primitives du SNC les plus agressives de l’adulte. Les causes d’échec thérapeutiques sont multiples, comme une résistance des cellules tumorales à l’apoptose, l’existence de cellules souches cancéreuses ou un microenvironnement pro-tumoral. La découverte de molécules thérapeutiques qui pourraient avoir une action pléiotrope est particulièrement attractive. Dans ce contexte nous nous sommes intéressés aux mimétiques de Smac (MS), antagonistes des inhibiteurs de l’apoptose (IAP), qui inhibent le plus souvent cIAP1, cIAP2, XIAP et ML-IAP. Nous avons recherché si les IAP pouvaient être des cibles thérapeutiques dans les GBs humains en étudiant leur expression et leurs valeurs pronostiques éventuelles : les IAP sont exprimés dans les GBs et ML-IAP est associé à un plus mauvais pronostic. Nous avons choisi d’utiliser pour la suite de nos expériences, un MS qui avait une action sur les IAP et en particulier ML-IAP : le GDC-0152. Le GDC-0152 induit l’apoptose in vitro, augmente la survie des souris porteuses de GB et ralentit la croissance tumorale in vivo. Ensuite nous avons recherché si l’effet du GDC-0152 pouvait être différent en fonction du taux d'oxygène. En effet, les GBs sont des tumeurs hypoxiques. Nous avons cultivé en normoxie et en hypoxie, quatre lignées de cellules souches de GBs. En normoxie, le GDC-0152 induit la différenciation des cellules souches (voie NF-κB) et en hypoxie il induit l’apoptose et diminue la prolifération cellulaire (voie ATR).Ces travaux soulignent l’importance du modèle préclinique utilisé dans la caractérisation de l'effet de nouvelles molécules et le potentiel thérapeutique des MS dans les GBs. / Glioblastomas (GBs) are the most aggressive primary brain tumors in adults. The causes of therapeutic failure are unknown and are multiples, such as tumor cell resistance to apoptosis, the presence of cancer stem cells or a pro-tumor microenvironment. Thus, the discovery of therapeutic molecules with pleiotropic action is particularly interesting. In this context, we are interested in smac mimetics (SM), antagonists of inhibitor of apoptosis proteins (IAPs) and most often antagonize cIAP1, cIAP2, XIAP and ML-IAP.We investigated whether IAPs could be attractive therapeutic targets in human GBs by studying their expression and their possible prognostic values. All IAPs were expressed in various degrees in GBs and ML-IAP was associated with a worse prognosis. Therefore, we chose GDC-0152 for the rest of our experiments because it antagonizes the different IAPs and in particular ML-IAP. We showed that GDC-0152 induces apoptosis in vitro, increases the survival of GB-bearing mice and slows tumor growth in vivo.We investigated whether the effect of GDC-0152 could be different depending on the oxygen level. Indeed, GBs are part of the most hypoxic tumors. For this purpose, four GB stem cell lines were grown in normoxia and hypoxia. We found that GDC-0152 has an anti-tumor effect regardless of oxygen level, but the signaling pathways involved were different. In normoxia, GDC-0152 induces differentiation of GB stem cells (NF-κB pathway) and in hypoxia it induces apoptosis and decreases cell proliferation (ATR pathway).This work highlights the importance of the preclinical model used in the characterization of a new molecule effects and the therapeutic potential of SM in GBs.